Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration
The objective of the study is to address research questions concerning the preclinical and prodromal stage of Alzheimer's disease, more specifically to address pathways of disease development, providing evidence to the biological mechanisms that may explain observed relationships.
Overview
- Acronym
- ALBION
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 2018 -
- General Information on Follow Up (profile, frequency)
-
All participants are evaluated annually after their baseline assessment. Participants are followed up longitudinally for a period of at least 10 years.
- Recruitment Target
-
- Individuals
- Number of Participants
- 112
- Number of Participants with Biological Samples
- 112
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Paper
Kalligerou F, Ntanasi E, Voskou P, et al. Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data. Postgrad Med. 2019 Sep;131(7):501-508.
PUBMED 31483196Timeline
Population
ALBION population
The population is composed of individuals aged 40 years or older who are even minimally concerned about their current cognitive status or are solely concerned about their future cognitive performance. They can be either cognitively normal (CN) or have at most mild cognitive deficits (MCI) but clearly, do not meet the criteria for dementia diagnosis.
Selection Criteria
- Minimum age
-
40
- Countries
-
- Greece
- Territory
- Athens
- Health Status
-
- All dementia patients were excluded from this study. Additional exclusion criteria contain: neurological, psychiatric or medical conditions associated with a high risk of cognitive impairment or dementia including but not limited to Huntington’s disease, multiple sclerosis, Parkinson’s disease, Down syndrome, active alcohol/ drug abuse or major psychiatric conditions including, not limited to, major depressive disorder, schizophrenia and bipolar disorder.
Sources of Recruitment
- Specific Population
-
- Clinic patients
Sample Size
- Number of Participants
- 112
- Number of Participants with Biological Samples
- 112
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ALBION - Baseline |
|
|
2018 | 2018 |
| 1 | ALBION - Visit 2 |
|
2019 | 2019 | |
| 2 | ALBION - Visit 3 |
|
|
2020 | 2020 |
| 3 | ALBION - Visit 4 |
|
2021 | 2021 |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2023-08-10T18:18:54.250